The U.S. medical digital imaging system market size was valued at USD 4.75 billion in 2023 and it is predicted to surpass around USD 9.82 billion by 2033 with a CAGR of 7.53% from 2024 to 2033.
The U.S. medical digital imaging system market is experiencing significant growth driven by technological advancements, increasing demand for diagnostic imaging procedures, and the rising prevalence of chronic diseases. Digital imaging systems have revolutionized medical diagnostics by offering enhanced image quality, faster processing times, and greater accessibility to patient data.
The growth of the U.S. medical digital imaging system market is driven by the technological advancements continue to enhance the capabilities of digital imaging systems, resulting in improved image quality and diagnostic accuracy. Increasing demand for diagnostic imaging procedures, driven by the rising prevalence of chronic diseases, is also contributing to market growth. Integration of artificial intelligence (AI) into digital imaging systems is enabling automated analysis and interpretation of medical images, leading to faster and more accurate diagnoses. Additionally, the shift towards value-based care models and the adoption of telemedicine are driving the demand for digital imaging systems that offer cost-effective solutions and remote accessibility. These factors combined are creating a conducive environment for sustained growth in the U.S. medical digital imaging system market.
In 2023, the CT segment dominated with a market share of 26%, a position it's poised to maintain throughout the forecast period. CT technology offers superior imaging of internal organs compared to conventional radiography, owing to its ability to capture detailed pictures. The segment's growth is fueled by the development of high-precision CT scanners that integrate advanced technologies such as AI & ML, alongside advanced visualization systems.
Meanwhile, the nuclear imaging segment is anticipated to exhibit the fastest growth in the forecast period. This growth is propelled by the widespread adoption of Single-photon emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) technologies in nuclear diagnostic procedures. Key factors driving this segment include affordability, device usability, suitable half-life of radioisotopes, and a diverse range of applications. Notably, oncology accounts for approximately 90% of clinical PET scan procedures, with PET increasingly utilized in translational research for developing novel therapies and diagnostic approaches tailored to lung diseases.
In 2023, the 3D/4D imaging segment captured the largest market share, accounting for 65%. This segment is poised for significant growth throughout the forecast period. The detailed imaging provided by 3D and 4D technologies facilitates more accurate disease diagnosis, offering exceptional quality images of organs like the lungs, heart, and brain rapidly and non-invasively, often within seconds. These technologies are instrumental in detecting various conditions such as blood clots, diseases, infections, and hemorrhages.
Continuous technological advancements in 3D/4D imaging solutions enable precise and real-time visualization of the human body, minimizing distortion. 4D imaging, in particular, offers the additional capability of real-time movement visualization alongside the benefits of 3D technology. The market for 3D and 4D imaging systems is expected to witness substantial growth in the coming years, driven by increasing adoption in fetal monitoring and other medical applications.
By Type
By Technology
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Medical Digital Imaging System Market
5.1. COVID-19 Landscape: U.S. Medical Digital Imaging System Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. U.S. Medical Digital Imaging System Market, By Type
8.1. U.S. Medical Digital Imaging System Market, by Type, 2024-2033
8.1.1. MRI
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. X-ray
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Ultrasound
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. CT
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Nuclear Imaging
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. U.S. Medical Digital Imaging System Market, By Technology
9.1. U.S. Medical Digital Imaging System Market, by Technology, 2024-2033
9.1.1. 2D
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. BnW
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Color
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. 3D/4D
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. U.S. Medical Digital Imaging System Market, Regional Estimates and Trend Forecast
10.1. U.S.
10.1.1. Market Revenue and Forecast, by Type (2021-2033)
10.1.2. Market Revenue and Forecast, by Technology (2021-2033)
Chapter 11. Company Profiles
11.1. Koninklijke Philips N.V
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. GE Healthcare
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Siemens Healthineers
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Esaote SPA
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Canon Medical Systems Corporation
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hologic
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hitachi
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Shimadzu
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms